PROSPECTIVE RANDOMIZED COMPARISON OF HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY VERSUS alpha-BLOCKER TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
1999; Lippincott Williams & Wilkins; Volume: 161; Issue: 1 Linguagem: Inglês
10.1016/s0022-5347(01)62084-6
ISSN1527-3792
AutoresBob Djavan, Claus G. Roehrborn, Shahrokh F. Shariat, Keywan Ghawidel, Michael Marberger,
Tópico(s)Cardiac electrophysiology and arrhythmias
ResumoNo AccessJournal of UrologyClinical Urology: Original Articles1 Jan 1999PROSPECTIVE RANDOMIZED COMPARISON OF HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY VERSUS alpha-BLOCKER TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA BOB DJAVAN, CLAUS G. ROEHRBORN, SHAHROKH SHARIAT, KEYWAN GHAWIDEL, and MICHAEL MARBERGER BOB DJAVANBOB DJAVAN , CLAUS G. ROEHRBORNCLAUS G. ROEHRBORN , SHAHROKH SHARIATSHAHROKH SHARIAT , KEYWAN GHAWIDELKEYWAN GHAWIDEL , and MICHAEL MARBERGERMICHAEL MARBERGER View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)62084-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We compare directly the efficacy and safety of targeted high energy transurethral microwave thermotherapy with alpha-blocker treatment for benign prostatic hyperplasia (BPH). Materials and Methods: In this randomized prospective study 52 patients with symptomatic BPH received terazosin and 51 underwent high energy transurethral microwave therapy with topical anesthesia. Patient evaluation included determination of International Prostate Symptom Score (I-PSS), peak flow rate and quality of life score before transurethral microwave therapy or terazosin and periodically up to 6 months thereafter. Results: At 2-week followup the terazosin group transiently exhibited significantly greater improvement than the transurethral microwave therapy group in mean values of all 3 primary efficacy parameters of I-PSS, peak flow rate and quality of life score. At 12 weeks and 6 months this pattern was reversed, and the transurethral microwave therapy group achieved significantly greater improvement than the terazosin group in mean I-PSS, peak flow rate and quality of life score. By 6 months 78.4, 64.7 and 84.3% of the transurethral microwave therapy group demonstrated a 50% or greater improvement in I-PSS, peak flow rate and quality of life score, respectively, compared with 32.7, 9.6 and 40.4% of the terazosin group, respectively. Nine patients in the terazosin group and 1 in the transurethral microwave therapy group withdrew from study because of side effects or lack of treatment efficacy. Conclusions: Terazosin afforded more rapid improvement in symptoms, voiding function and quality of life in BPH patients. High energy transurethral microwave therapy offered markedly superior clinical outcomes at 12 weeks to 6 months. References 1 : The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur. Urol.1996; 30: 369. Google Scholar 2 : The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N. Engl. J. Med.1996; 335: 533. Google Scholar 3 : The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology1996; 47: 159. Google Scholar 4 : Transurethral microwave treatment for benign prostatic hypertrophy: a randomized controlled clinical trial. Brit. Med. J.1993; 306: 1293. Google Scholar 5 : Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet1993; 341: 14. Crossref, Medline, Google Scholar 6 : A sham controlled trial of transurethral microwave therapy with subsequent treatment of the control group. J. Urol.1994; 152: 453. Link, Google Scholar 7 : Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology1994; 44: 58. Crossref, Medline, Google Scholar 8 : Transurethral microwave thermotherapy versus transurethral catheter therapy for benign prostatic hyperplasia. Eur. Urol.1994; 26: 6. Crossref, Medline, Google Scholar 9 : Transurethral microwave thermotherapy v sham treatment: double-blind randomized study. J. Endourol.1996; 10: 565. Google Scholar 10 : A 12-month study of the placebo effect in transurethral microwave thermotherapy. Brit. J. Urol.1996; 77: 221. Crossref, Medline, Google Scholar 11 : A high efficiency microwave thermoablation system for the treatment of benign prostatic hyperplasia: results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial. Urology1998; 51: 731. Google Scholar 12 : A novel transurethral microwave thermoablation system to treat benign prostatic hyperplasia: results of a prospective multicenter clinical trial. J. Urol.1997; 158: 112. Link, Google Scholar 13 : Tolerability of high-energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J. Urol.1998; 160: 772. Abstract, Google Scholar 14 : Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. Urology1997; 50: 55. Google Scholar 15 : Benign Prostatic Hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J. Urol.1995; 154: 1770. Link, Google Scholar 16 : Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. J. Urol.1996; 155: 1317. Link, Google Scholar 17 : Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South. Med. J.1997; 90: 509. Google Scholar 18 : A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol.1992; 148: 1467. Link, Google Scholar 19 : Terazosin in the treatment of benign prostatic hyperplasia. Arch. Fam. Med.1993; 2: 929. Crossref, Medline, Google Scholar 20 : Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable?. J. Urol.1997; 158: 1829. Link, Google Scholar Department of Urology, University of Vienna, Vienna, Austria, and the Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byLaguna M, Kiemeney L, Debruyne F and de la Rosette J (2018) Baseline Prostatic Specific Antigen Does Not Predict The Outcome Of High Energy Transurethral Microwave ThermotherapyJournal of Urology, VOL. 167, NO. 4, (1727-1730), Online publication date: 1-Apr-2002. Volume 161Issue 1January 1999Page: 139-143 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information BOB DJAVAN More articles by this author CLAUS G. ROEHRBORN More articles by this author SHAHROKH SHARIAT More articles by this author KEYWAN GHAWIDEL More articles by this author MICHAEL MARBERGER More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)